These kinase inhibitors include vemurafenib and dabrafenib (BRAF inhibitors; BRAFi) and trametinib (MEK inhibitor), which attenuate the signalling flux of the mitogen-activated protein kinase pathway that is constitutively active in ~90% of melanoma.2 Nevertheless, despite initially rapid and deep tumour responses in most metastatic melanoma patients, these agents have the major drawback of drug resistance, which limits the median progression-free interval to approximately 9–10 months.2 Here, BRAF is linked to metastatic melanoma.